Literature DB >> 20849965

Validation of a cell-based assay to differentiate between the cytotoxic effects of elapid snake venoms.

Yasmean Kalam1, Geoffrey K Isbister, Peter Mirtschin, Wayne C Hodgson, Nicki Konstantakopoulos.   

Abstract

INTRODUCTION: Acanthophis genus (i.e. death adders) and the Naja genus (i.e. cobras) belong to the family elapidae. The current study compared the in vitro cytotoxicity of venoms from four Acanthophis spp. and three Naja spp. on rat aortic smooth muscle cells, A7r5, and rat skeletal muscle cells, L6. The ability of CSL death adder antivenom and SAIMR antivenom, for Acanthophis spp. and Naja spp. venom respectively, to negate the cytotoxicity was also examined.
METHODS: A cell proliferation assay was used to determine cell viability following treatment with venom in the presence or absence of antivenom. Sigmoidal growth curves were obtained, and IC(50) values were determined.
RESULTS: Acanthophis spp. and Naja spp. venoms produced concentration-dependent inhibition of cell proliferation in both cell lines. Naja spp. venoms were significantly more cytotoxic than the most potent Acanthophis venom (i.e. A. antarcticus) in both cell lines. Naja spp. venoms also displayed higher sensitivity in L6 cells. SAIMR antivenom significantly inhibited the cytotoxic actions of all Naja spp. venoms in both A7r5 and L6 cells. However, death adder antivenom (CSL Ltd) was unable to negate the cytotoxic effects of Acanthophis spp. venoms. DISCUSSION: Concentrations of the predominantly cytotoxic Naja spp. venoms used were approximately three times less than the predominantly neurotoxic Acanthophis spp. venoms. SAIMR antivenom was partially effective in neutralising the effects of Naja spp. venoms. Death adder antivenom (CSL Ltd) was not effective in negating the cytotoxic effects of venom from Acanthophis spp. These results indicate that the cell-based assay is suited to the examination of cytotoxic snake venoms and may be used in conjunction with organ bath experiments to pharmacologically characterise snake venoms. Furthermore, the results suggest that the use of a skeletal muscle cell line is likely to be more clinically relevant for the examination of cytotoxic snake venoms.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20849965     DOI: 10.1016/j.vascn.2010.09.001

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  9 in total

1.  Cytotoxicity of Venoms and Cytotoxins from Asiatic Cobras (Naja kaouthia, Naja sumatrana, Naja atra) and Neutralization by Antivenoms from Thailand, Vietnam, and Taiwan.

Authors:  Ho Phin Chong; Kae Yi Tan; Bing-Sin Liu; Wang-Chou Sung; Choo Hock Tan
Journal:  Toxins (Basel)       Date:  2022-05-10       Impact factor: 5.075

Review 2.  Therapeutic potential of snake venom in cancer therapy: current perspectives.

Authors:  Vivek Kumar Vyas; Keyur Brahmbhatt; Hardik Bhatt; Utsav Parmar
Journal:  Asian Pac J Trop Biomed       Date:  2013-02

3.  The in vitro toxicity of venoms from South Asian hump-nosed pit vipers (Viperidae: Hypnale).

Authors:  Kalana Maduwage; Wayne C Hodgson; Nicki Konstantakopoulos; Margaret A O'Leary; Indika Gawarammana; Geoffrey K Isbister
Journal:  J Venom Res       Date:  2011-06-08

4.  In vitro toxic effects of puff adder (Bitis arietans) venom, and their neutralization by antivenom.

Authors:  Steven Fernandez; Wayne Hodgson; Janeyuth Chaisakul; Rachelle Kornhauser; Nicki Konstantakopoulos; Alexander Ian Smith; Sanjaya Kuruppu
Journal:  Toxins (Basel)       Date:  2014-05-19       Impact factor: 4.546

5.  Snake venom causes apoptosis by increasing the reactive oxygen species in colorectal and breast cancer cell lines.

Authors:  Abdulrahman Khazim Al-Asmari; Anvarbatcha Riyasdeen; Mohammad Hamed Al-Shahrani; Mozaffarul Islam
Journal:  Onco Targets Ther       Date:  2016-10-20       Impact factor: 4.147

6.  How the Cobra Got Its Flesh-Eating Venom: Cytotoxicity as a Defensive Innovation and Its Co-Evolution with Hooding, Aposematic Marking, and Spitting.

Authors:  Nadya Panagides; Timothy N W Jackson; Maria P Ikonomopoulou; Kevin Arbuckle; Rudolf Pretzler; Daryl C Yang; Syed A Ali; Ivan Koludarov; James Dobson; Brittany Sanker; Angelique Asselin; Renan C Santana; Iwan Hendrikx; Harold van der Ploeg; Jeremie Tai-A-Pin; Romilly van den Bergh; Harald M I Kerkkamp; Freek J Vonk; Arno Naude; Morné A Strydom; Louis Jacobsz; Nathan Dunstan; Marc Jaeger; Wayne C Hodgson; John Miles; Bryan G Fry
Journal:  Toxins (Basel)       Date:  2017-03-13       Impact factor: 4.546

7.  Treatment outcomes among snakebite patients in north-west Ethiopia-A retrospective analysis.

Authors:  Inge Steegemans; Kassaye Sisay; Ernest Nshimiyimana; Gashew Gebrewold; Turid Piening; Endale Menberu Tessema; Birhanu Sahelie; Gabriel Alcoba; Fikre Seife Gebretsadik; Dirk Essink; Simon Collin; Emiliano Lucero; Koert Ritmeijer
Journal:  PLoS Negl Trop Dis       Date:  2022-02-09

8.  Non-neurotoxic activity of Malayan krait (Bungarus candidus) venom from Thailand.

Authors:  Mongkon Charoenpitakchai; Kulachet Wiwatwarayos; Nattapon Jaisupa; Muhamad Rusdi Ahmad Rusmili; Supachoke Mangmool; Wayne C Hodgson; Chetana Ruangpratheep; Lawan Chanhome; Janeyuth Chaisakul
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2018-03-09

9.  Engineered nanoparticles bind elapid snake venom toxins and inhibit venom-induced dermonecrosis.

Authors:  Jeffrey O'Brien; Shih-Hui Lee; José María Gutiérrez; Kenneth J Shea
Journal:  PLoS Negl Trop Dis       Date:  2018-10-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.